Diagnostic study using a newly developed amiloid imaging PET tracer: [18F]FPYBF-2 in adult patients with Down syndrome.

Diagnostic study using a newly developed amiloid imaging PET tracer: [18F]FPYBF-2 in adult patients with Down syndrome. - Diagnostic study using a newly developed amiloid imaging PET tracer: [18F]FPYBF-2 in adult patients with Down syndrome.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012298

Enrollment

Registered

2013-11-14

Start date

2013-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Down syndrome and its related diseases

Interventions

injection of radioisotope

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are diagnosed as Down syndrome and its related diseases and are suspected to have cognitive impairment. Object: 6 years old or older (the condition of age restriction was changed and approved by our ethical commettee at Sep. 29, 2015)

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Evaluation of diagnostic usefulness of [18F]FPYBF-2 in patients with Down syndrome and its related diseases who are clinically diagnosed as cognitive impairment (comparison between clinical diagnosis and imaging diagnosis).	—

Secondary

Measure	Time frame
Evaluation of prognostic usefulness of [18F]FPYBF-2 in patients with mild cognitive imapairment who developed dementia later.	—

Countries

Japan

Contacts

Public ContactShigenori Shimomura

Shiga Medical Center, Research Institute head office

kenkyu@res.med.shiga-pref.jp077-582-6034

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026